Status:
UNKNOWN
Imaging of Type 1 Diabetes Progression
Lead Sponsor:
Jason Gaglia
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Harvard Medical School (HMS and HSDM)
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
18+ years
Brief Summary
Type 1 diabetes results from the autoimmune destruction of the insulin-producing beta cells of the islets of Langerhans of the pancreas. Initially, diabetes is usually clinically silent with immune ce...
Detailed Description
This study is designed to monitor changes associated with the development of autoimmune diabetes. A magnetic resonance imaging (MRI) based technique will be used to noninvasively measure changes withi...
Eligibility Criteria
Inclusion
- Participation in a collaborating diabetes clinical trial
- Able to understand written consent document and HIPAA authorization prior to initiation of study related procedures and are willing to participate
Exclusion
- Known allergy to ferumoxytol or iron
- Individuals who are pregnant or lactating
- Iron saturation above the upper limit of normal
- Individuals with a counter-indication to MRI, such as the presence of metallic prostheses or implanted metal device (e.g., infusion pump, defibrillator)
- Individuals with known clinical conditions that may lead to iron overload including hemochromatosis, cirrhosis, or sickle cell disease
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01521520
Start Date
January 1 2012
Last Update
April 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114